M.D. PhDIntellia Therapeutics, Cambridge, MA, USACambridge, Massachusetts, United States
PB1076 - Reduction of plasma kallikrein by in vivo CRISPR-based gene editing of KLKB1 does not alter coagulation in patients with hereditary angioedema
Tuesday, June 25, 202413:45 – 14:45 ICT
